HOME >> BIOLOGY >> NEWS
Leibniz Prize winners 2003

cal Cytobiology and Cytopathology at the Philipps University in Marburg.

Prof. Dr. Christof Niehrs (40), development biology/genetics/zoology, German Cancer Research Centre in Heidelberg (1.55 million euros)

Christof Niehrs is well-known around the world as the development biologist who has answered many of the central questions in his field. His answers, together with an understanding of the underlying genomes, have laid the foundations for future contributions to questions which have not yet been answered, such as the question of shape and size in biology. Christof Niehrs has made his name in three fields of research:

    For studying mesoderm formation in amphibians (xenopus) he developed a gene expression screen for analysing gene activity in xenopus embryos. In the course of this research a number of control genes were identified which play a part in the development of the embryo.

    A second key focus of Niehrs' work relates to the Spemann organiser function, a piece of tissue from the amphibian embryo which has the power to induce a complete new embryo following transplantation.

    Possibly the most spectacular work presented by Christof Niehrs has been on the development mechanism of the embryo's head; this work has helped to solve one of the central problems which hampered even Spemann's research results.

Christof Niehrs studied biochemistry at the Free University of Berlin. After obtaining his doctorate there he moved to a postdoctoral post at the University of California in Los Angeles. In the years following 1994 he developed his own study group at the German Cancer Research Centre in Heidelberg. Following his qualification as a university professor in 1997, at the age of 36 he was offered a C4 professorship in biochemistry at the University of Bochum. Since then he has been offered professorships at the University of Karlsruhe and at the German Cancer Research Centre in Heidelberg.

Prof. Dr. Fer
'"/>

Contact: Ursula Rogmans-Beucher
ursula.rogmans-beucher@dfg.de
49-228-885-2726
Deutsche Forschungsgemeinschaft
3-Apr-2003


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. Leibniz Prizewinners 2004
2. Prizes awarded in the 2002 Gottfried Wilhelm Leibniz Programme
3. Leibniz Prize Winners 1999 - Most Highly Endowed German Promotional Prize For Ten Scientists
4. Half-million dollar landmark achieved for the Methuselah Mouse Prize
5. Winner of 2004 EMBO Science Writing Prize announced
6. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
7. Stuart Lipton honored with Jung Prize for Medicine
8. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
9. Scripps research scientist wins 2004 Koch Prize
10. Ohio State wetlands professor wins prestigious Water Prize
11. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Leibniz Prize winners

(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: